Archives of rheumatology最新文献

{"title":"Sixth cranial nerve palsy in giant cell arteritis: A systematic review.","authors":"Haruki Sawada, Yoshito Nishimura, Hiromichi Tamaki","doi":"10.46497/ArchRheumatol.2024.10528","DOIUrl":"10.46497/ArchRheumatol.2024.10528","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to review and describe isolated sixth cranial nerve or abducens nerve palsy that may present with subtle ophthalmoplegia in patients with giant cell arteritis (GCA).</p><p><strong>Materials and methods: </strong>In this systematic review following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Scoping Reviews, MEDLINE and EMBASE were searched for all peer-reviewed articles using the keywords \"cranial nerve six,\" \"abducens nerve,\" and \"giant cell arteritis\" from their inception to December 22, 2022.</p><p><strong>Results: </strong>Twenty-five articles, including seven observational studies and 18 cases, were included. While the incidence and prevalence of sixth nerve palsy in GCA were variable, up to 48% of diplopia in GCA were attributed to the sixth cranial nerve palsy, according to the observational studies included. While 88.2% had a resolution of symptoms with 40-50 mg/day of prednisone-equivalent corticosteroids, it took a median of 24.5 days until the resolution of symptoms from the initiation of treatment.</p><p><strong>Conclusion: </strong>This review summarizes the current understanding of the characteristics of sixth nerve palsy in GCA. While most patients may have reversible clinical courses, a few can suffer from persistent ophthalmoplegia, which is a potentially missed yet crucial clinical finding in GCA. Increased awareness of the sixth nerve palsy in GCA is crucial.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"479-487"},"PeriodicalIF":1.1,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel use of interleukin-1 antagonists in male familial Mediterranean fever patients with infertility: Case series.","authors":"Bugra Egeli, Kerem Parlar, Basak Filiz, Ibrahim Durucan, Serdal Ugurlu","doi":"10.46497/ArchRheumatol.2024.10269","DOIUrl":"10.46497/ArchRheumatol.2024.10269","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"474-475"},"PeriodicalIF":1.1,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity and reliability of the Turkish version of Exercise Benefits/ Barriers Scale: Perceived exercise benefits and barriers of patients with different axial spondyloarthritis subtypes.","authors":"Devrim Can Sarac, Elif Durak Ediboglu, Derya Ozer Kaya, Gozde Duran, Emre Alp Akatay, Sercan Gucenmez, Servet Akar, Deniz Bayraktar","doi":"10.46497/ArchRheumatol.2024.10720","DOIUrl":"10.46497/ArchRheumatol.2024.10720","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to translate the Exercise Benefits/Barriers Scale (EBBS) into Turkish and investigate the perceptions of Turkish-speaking patients with different axial spondyloarthritis (axSpA) subtypes regarding exercise benefits and barriers.</p><p><strong>Patients and methods: </strong>This validation study was conducted between June 2018 and December 2021. Patients with axSpA were consecutively assessed regarding physical (age, sex and body mass index) and disease-related characteristics (disease activity, spinal mobility, functional status, quality of life, health status, emotional status, and kinesiophobia). Eligible participants were asked to complete the EBSS and other outcome measurements during their initial visits. EBBS was readministered 7 to 14 days later.</p><p><strong>Results: </strong>One hundred forty-eight patients (89 males, 59 females; mean age: 44.3±11.8 years; range, 19 to 65 years) were included in the study. Of the patients, 108 had radiographic axSpA, and 40 had nonradiographic axSpA. EBBS-Barriers and EBBS-Benefits subscales demonstrated adequate internal consistency (Cronbach's alphas of 0.82 and 0.95, respectively) and test-retest reliability (intraclass correlation coefficients of 0.837 and 0.807, respectively). No significant differences were observed between axSpA subtypes regarding EBBS-Barriers (p=0.12) and EBBS-Benefits (p=0.10) subscales. Significant relationships were detected between kinesiophobia and EBBS-Barriers scores (r=-0.424, p<0.01), as well as EBBS-Benefits scores (r=-0.344, p<0.01) for all patients. EBBS-Benefits scores were correlated to health status (r=-0.412, p=0.08) and quality of life (r=-0.394, p=0.01) in patients with nonradiographic axSpA.</p><p><strong>Conclusion: </strong>According to our results, the Turkish EBBS is a valid and reliable tool for patients with axSpA. Perceptions of the patients with axSpA regarding exercise barriers and benefits do not differ according to the disease subtype. It appears that kinesiophobia may be an important parameter regarding exercise perception in axSpA.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"447-458"},"PeriodicalIF":1.1,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The hidden oncological challenge in Sjögren's syndrome with a focus on pharyngeal cancer.","authors":"Wan-Hee Yoo, Kyoung Min Kim, Yunjung Choi","doi":"10.46497/ArchRheumatol.2024.10748","DOIUrl":"10.46497/ArchRheumatol.2024.10748","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"471-473"},"PeriodicalIF":1.1,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New and future perspectives in familial Mediterranean fever and other autoinflammatory diseases.","authors":"Veysel Çam, Hülya Ercan Emreol, Seza Ozen","doi":"10.46497/ArchRheumatol.2024.10911","DOIUrl":"10.46497/ArchRheumatol.2024.10911","url":null,"abstract":"<p><p>Systemic autoinflammatory diseases are a group of disorders characterized by sterile episodes of inflammation resulting from defects in the innate immune system. In contrast to classical autoimmune diseases, where circulating autoantibodies and the adaptive immune system are involved, these conditions involve excessive presence of proinflammatory cytokines leading to inflammatory attacks. Excessive cytokine production, functional mutations in regulatory pathways, excessive interferon production, defects in the nuclear factor-kappa B signaling pathway, abnorARCHmal protein folding, and complement activation are the mechanisms leading to autoinflammatory diseases. A defect in the mTOR pathway and trained immunity are newly discovered possible causes in pathogenesis. Early onset and severe forms of classical rheumatological diseases have been more frequently associated with autoinflammatory diseases in the last decade. Therefore, monogenic autoinflammatory diseases should be considered in rheumatic diseases with family history, consanguinity, early onset, and severe disease. The combination of functional and genotyping research will help to identify unclassified patients. The optimal treatment strategy remains uncertain, functional studies such as interferon signature and cytokine profiling, may prove valuable in guiding the treatment process. Stem cell transplantation strategies in autoinflammatory diseases with partial response to biological therapies can be considered. Autoinflammatory diseases are becoming increasingly complex and are bringing new perspectives to already known rheumatic diseases. Although we have effective treatments, we are still far from personalized recommendations.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"331-338"},"PeriodicalIF":1.1,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional variations in psoriatic arthritis: Insights from a nationwide multicenter analysis in Türkiye.","authors":"Erkan Kılıç, Gamze Kılıç, İbrahim Tekeoğlu, Betül Sargın, Sevtap Acer Kasman, Hakan Alkan, Nilay Şahin, Gizem Cengiz, Nihan Cüzdan, İlknur Albayrak Gezer, Dilek Keskin, Cevriye Mülkoğlu, Hatice Reşorlu, İsmihan Sunar, Ajda Bal, Mehmet Tuncay Duruöz, Okan Küçükakkaş, Ozan Volkan Yurdakul, Meltem Alkan Melikoğlu, Yıldıray Aydın, Fikriye Figen Ayhan, Hatice Bodur, Mustafa Çalış, Erhan Çapkın, Gül Devrimsel, Kevser Orhan, Sami Hizmetli, Ayhan Kamanlı, Yaşar Keskin, Hilal Ecesoy, Öznur Kutluk, Nesrin Şen, Ömer Faruk Şendur, Sena Tolu, Murat Toprak, Tiraje Tuncer, Kemal Nas","doi":"10.46497/ArchRheumatol.2024.10591","DOIUrl":"10.46497/ArchRheumatol.2024.10591","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to investigate and compare clinical features, disease activity, and the overall disease burden among psoriatic arthritis (PsA) patients across seven distinct geographic regions in Türkiye.</p><p><strong>Patients and methods: </strong>A multicenter cross-sectional study involving 1,134 PsA patients from 25 referral centers across seven regions was conducted. Demographic and clinical characteristics, comorbidities, joint involvement, extra-articular manifestations, and disease activity measures were evaluated across regions.</p><p><strong>Results: </strong>A total of 1134 PsA patients from seven different geographic regions in Türkiye participated in this study. The highest number of participants was from the Marmara region (n=409), with subsequent representation from Central Anatolia (n=370), Aegean (n=139), Mediterranean (n=60), Black Sea (n=60), Eastern Anatolia (n=60), and Southeastern Anatolia (n=36) regions. There were significant variations in demographic profile, including age, body mass index, age of disease onset, educational status, comorbidities, and family history of both psoriasis and PsA. Clinical features, such as enthesitis, dactylitis, uveitis, and joint involvement, demonstrated significant variation across regions. Additionally, disease activity measures, including pain, patient and physician global assessments, acute phase reactants, disease activity indices, quality of life, and functional status, displayed considerable regional differences.</p><p><strong>Conclusion: </strong>This nationwide study revealed substantial regional diversity in demographic data, clinical characteristics, disease activity, and quality of life among PsA patients in Türkiye. These findings stress the need to customize treatment approaches to address regional needs and to conduct further research to uncover reasons for disparities. It is crucial to enhance region-specific approaches to improve patient care and outcomes for PsA.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"339-349"},"PeriodicalIF":1.1,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired Madelung's deformity as a cause of recurrent monoarthritis in a young patient.","authors":"Georges El Hasbani, Ali Jawad, Imad Uthman","doi":"10.46497/ArchRheumatol.2024.10548","DOIUrl":"10.46497/ArchRheumatol.2024.10548","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"467-470"},"PeriodicalIF":1.1,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of ex vivo ozone injection into the synovial fluid in patients with knee osteoarthritis: A controlled clinical trial.","authors":"Emre Ata, Semiha Özgüç, Mustafa Hüseyin Temel, Hakan Beyaztaş, Selman Aktaş, Eray Metin Güler","doi":"10.46497/ArchRheumatol.2024.10375","DOIUrl":"10.46497/ArchRheumatol.2024.10375","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to examine the effect of varying ozone doses on proinflammatory cytokine levels in the synovial fluid collected from individuals with knee osteoarthritis.</p><p><strong>Patients and methods: </strong>The controlled clinical trial was conducted with 82 patients (61 females, 21 males; mean age: 63.1±10.0 years; range, 40 to 73 years) between 21 April 2023 and 20 May 2023. Synovial fluid samples were collected from the patients under ultrasound guidance and divided into three tubes, one of which was not injected with ozone, and the other two were injected with 10 and 30 gamma (γ) ozone, respectively. The total antioxidant status, total oxidant status, oxidative stress index, interleukin (IL)-1 beta (β), IL-6, and tumor necrosis factor-alpha (TNF-α) in the joint fluids were measured.</p><p><strong>Results: </strong>The oxidative stress index and IL-1 β, IL-6, and TNF-α levels in the synovial fluid were lower at 10 and 30 γ compared to 0 and 10 γ, respectively. <i>In vitro</i> ozone injection at 30 gamma was more effective in reducing proinflammatory cytokines in the synovial fluid than that at 10 and 0 γ. Ozone injection into the pathological joint fluid was more effective in terms of total antioxidant status at 10 and 30 γ compared to 0 and 10 γ, respectively. No significant difference in total oxidant status was observed between the groups.</p><p><strong>Conclusion: </strong>This study showed that <i>in vitro</i> ozone injection at 30 γ was more effective in reducing proinflammatory cytokines in the synovial fluid and in improving total antioxidant status than that at 10 and 0 γ. The results showed the potential significance of the ozone injection dosage in treating knee osteoarthritis.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"459-466"},"PeriodicalIF":1.1,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gout and erectile dysfunction: Increased carotid intima-media thickness is independently associated with greater likelihood for erectile dysfunction.","authors":"Ece Yigit, Serdar Yasar, Meryem Can, Zeki Bayraktar","doi":"10.46497/ArchRheumatol.2024.10486","DOIUrl":"10.46497/ArchRheumatol.2024.10486","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to compare gout patients and healthy subjects in terms of erectile dysfunction, carotid intima-media thickness (CIMT), and other variables and to investigate the relationship between CIMT and erectile dysfunction.</p><p><strong>Patients and methods: </strong>This cross-sectional study was conducted with 134 male gout patients (median age: 56 years; range, 48 to 62 years) and 104 healthy males (median age: 47 years; range, 40.5 to 54.5 years) between September 2022 and June 2023. Age, comorbidities, height, weight, laboratory results, gout treatment data, insulin resistance evaluated by the homeostatic model assessment for insulin resistance, presence and severity of erectile dysfunction evaluated by the six-item International Index of Erectile Function erectile function domain (IIEF-EF), and CIMT measured by ultrasound were assessed.</p><p><strong>Results: </strong>Hypertension, hyperlipidemia, greater insulin resistance, erectile dysfunction, and bilaterally increased CIMT were significantly more common in the gout group. The mean IIEF-EF score of gout patients was significantly lower than that of controls. Multivariable logistic regression revealed increased CIMT as the sole parameter independently associated with erectile dysfunction (p=0.010). When both groups were categorized into CIMT-based subsets, erectile dysfunction was present in 97.9% of patients with coexistence of gout and increased CIMT (≥0.9 mm), a significantly higher proportion compared to the other three subsets (p<0.001).</p><p><strong>Conclusion: </strong>Increased CIMT was the only factor independently associated with a greater likelihood of erectile dysfunction in patients with and without gout; however, coexistence of gout and increased CIMT appears to result in a significantly elevated risk for erectile dysfunction.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"393-403"},"PeriodicalIF":1.1,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome.","authors":"Nevsun Pihtili Taş, Rabia Aydogan Baykara, Ayhan Kamanli, Ali Gürbüz, Erkan Cure, Medine Cumhur Cüre, Mehmet Erdem, Tugce Tasar Yildirim","doi":"10.46497/ArchRheumatol.2024.10462","DOIUrl":"10.46497/ArchRheumatol.2024.10462","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the potential roles of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and apelin in the etiology of fibromyalgia syndrome (FS).</p><p><strong>Patients and methods: </strong>The retrospective study was conducted between May 2022 and February 2023. Fifty-eight female FS patients (mean age: 45.2±9.9 years; range, 25 to 66 years) and 30 age- and body mass index-matched control subjects (mean age: 43.1±9.9 years; range, 26 to 67 years) were included in the study. Apelin and PCSK9 levels of all individuals were measured using appropriate methods.</p><p><strong>Results: </strong>The levels of PCSK9 (173.2±62.2 <i>vs.</i> 75.1±44.1, p<0.001) and apelin (354.6±195.5 <i>vs.</i> 229.0±83.2, p<0.001) were significantly higher in patients with FS compared to the control group. A positive correlation was found between PCSK9 and apelin levels and various measures, including the Fibromyalgia Impact Questionnaire (FIQ), Symptom Severity Scale (SSS), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Inventory (BDI). Additionally, there was a positive correlation between apelin levels and FIQ, SSS, PSQI, Beck Anxiety Inventory, and BDI scores. The optimal cutoff value for PCSK9 in predicting FS was 110.0 ng/mL, with a sensitivity of 84.5% and specificity of 83.9% (area under the curve [AUC]=0.920, 95% confidence interval [CI]: 0.852-0.987, p<0.001). For apelin, the optimal cutoff value for predicting FS was 258.8 ng/L, with a sensitivity of 63.8% and specificity of 64.5% (AUC=0.732, 95% CI: 0.623-0.840, p<0.001).</p><p><strong>Conclusion: </strong>Our findings suggest that PCSK9 may play a role in FS etiology and potentially contribute to oxidative stress. Increased apelin levels may be a compensatory response to high oxidative stress, possibly leading to hyperalgesia. Both PCSK9 and apelin can be predictive markers for FS.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"375-383"},"PeriodicalIF":1.1,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}